Brief: Cortexyme Announces Clinical Hold On Atuzaginstat’S Investigational New Drug Application

IRulya Therapeutics

26/01/2022 13:50

Jan 26 (Reuters) - Cortexyme Inc  CRTX.O :
    * CORTEXYME ANNOUNCES CLINICAL HOLD ON ATUZAGINSTAT’S
INVESTIGATIONAL NEW DRUG APPLICATION
    * INTENDS TO PRIORITIZE DEVELOPMENT OF ITS NEXT GENERATION
GINGIPAIN INHIBITOR, COR588, IN ALZHEIMER'S DISEASE
    * IMMEDIATELY IMPLEMENTING A COST REDUCTION PROGRAM
    * CORTEXYME PLANS TO EXPLORE STRATEGIC ALTERNATIVES FOR ITS
CORONAVIRUS PROGRAM AND NON-ALZHEIMER'S INDICATIONS FOR COR388
    * CORTEXYME -RECEIVED LETTER FROM FDA ON JAN. 25, 2022
PLACING
FULL CLINICAL HOLD ON ATUZAGINSTAT'S (COR388) INVESTIGATIONAL
NEW DRUG APPLICATION
    * COR588 IS CURRENTLY COMPLETING A PHASE 1 SAD/MAD STUDY AND
RESULTS ARE EXPECTED IN Q2 2022
    * COMPANY PLANS TO PROVIDE ADDITIONAL UPDATES PENDING
CONTINUED
ENGAGEMENT WITH FDA

Source text for Eikon:  ID:nBw1SxdZ6a 
Further company coverage:  CRTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))